CIBC Bancorp USA’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273M Sell
3,165,935
-288,800
-8% -$24M 0.34% 65
2026
Q2
$233M Sell
3,454,735
-762,399
-18% -$50.8M 0.28% 85
2026
Q1
$265M Buy
+4,217,134
New +$294M 0.36% 66
2025
Q3
$4.61M Buy
+68,460
New +$5.42M 0.03% 416

Other funds holding DXCM

CIBC Bancorp USA's DXCM Position: Q3 2026 in Review

CIBC Bancorp USA reduced its DexCom (DXCM) stake by 8.4% in Q3 2026, selling an estimated $24M and leaving 3,165,935 shares worth $273M. The position accounts for 0.34% of the portfolio, ranked #65.

CIBC Bancorp USA first reported a position in DXCM in Q3 2025 and has held it in 4 quarters since. 1,043 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • CIBC Bancorp USA held 3,165,935 shares of DexCom worth $273M as of Q3 2026.
  • CIBC Bancorp USA sold 288,800 DexCom shares in Q3 2026, an estimated $24M.
  • DexCom made up 0.34% of CIBC Bancorp USA's portfolio in Q3 2026, its #65 holding.
  • CIBC Bancorp USA first reported a position in DexCom in Q3 2025 and has held it in 4 quarters since.
  • 1,043 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.